EXTON, Pa.--(BUSINESS WIRE)--Morphotek®, Inc., a subsidiary of Eisai Co., Ltd., announced today that it has signed a Cooperative Research and Development Agreement (CRADA) with the National Cancer Institute (NCI) for the development of therapeutic antibodies to a cancer-associated protein identified by NCI researchers. Morphotek will apply its proprietary MORPHODOMA® antibody technology to the development of novel therapeutic antibodies for use in the treatment of prostate cancer. The NCI will provide its expertise in evaluating the lead antibodies for therapeutic efficacy.
